Naratriptan
- Atc Codes:N02CC02
- CAS Codes:143388-64-1#121679-13-8
- PHARMGKB ID:143388-64-1#121679-13-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Antimigrin, Naramig, Naratriptan; Belgium: Naramig; Czech Republic: Naramig, Naratriptan; Denmark: Naragran; Estonia: Naramig; Finland: Naramig; France: Naramig; Germany: Formigran, Naramig, Naratriptan; Greece: Naramig, Naratriptan; Ireland: Naramerg, Naramig; Lithuania: Naramig; Netherlands: Naramig; Poland: Naramig, Naratriptan; Portugal: Naramig, Naratriptano; Slovakia: Naramig; Slovenia: Naramig; Spain: Naramig; Sweden: Naramig; UK: Naramig.
North America
Canada: Amerge; USA: Amerge.
Latin America
Argentina: Naramig; Brazil: Naramig.
Asia
Japan: Amerge.
Drug combinations
Chemistry
Naratriptan Hydrochloride: C~17~H~25~N~3~O~2~S HCl. Mw: 371.93. (1) 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride; (2) N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride. CAS-143388-64-1; CAS-121679-13-8 (naratriptan)(1993).
Pharmacologic Category
Antimigraine Agents; Selective Serotonin Agonists. Serotonin 5-HT~1B~,~1D~ Receptor Agonist. (ATC-Code: N02CC02).
Mechanism of action
Therapeutic effect for migraine is due to serotonin agonist activity.
Therapeutic use
Treatment of acute migraine headache with or without aura.
Pregnancy and lactiation implications
There are no adequate, well-controlled studies in pregnant women. Use only if potential benefit to mother outweighs potential risk to fetus. In animal studies, administration associated with embryolethality, fetal abnormalities, and pup mortality and growth retardation. Tremors observed in offspring of female rats when exposed to naratriptan late in gestation. Use with caution in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to naratriptan or any component of the formulation. Cerebrovascular, peripheral vascular disease (ischemic bowel disease), ischemic heart disease (angina pectoris, history of myocardial infarction, or proven silent ischemia), or in symptoms consistent with ischemic heart disease, coronary artery vasospasm, or Prinzmetal’s angina. Uncontrolled hypertension or patients who have received within 24 hours another 5-HT agonist or ergotamine-containing product. Known risk factors associated with coronary artery disease. Severe hepatic or renal disease (CrCl <15 mL/minute). Do not administer naratriptan in hemiplegic or basilar migraine.
Warnings and precautions
Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death reported with 5-HT~1~ agonist administration. Cerebral/subarachnoid hemorrhage and stroke reported with 5-HT~1~ agonist administration. Significant elevation in blood pressure, including hypertensive crisis reported on rare occasions with and without history of hypertension. Peripheral vascular ischemia and colonic ischemia reported with 5-HT~1~ agonists. Should not be given in risk factors for CAD without adequate cardiac evaluation. Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs or agents which reduce metabolism of naratriptan. Concurrent use of serotonin precursors not recommended. Only indicated for treatment of acute migraine.